Best Options Strategy for ZNTL
Looking for the best options strategy for Zentalis Pharmaceuticals, Inc. (ZNTL)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live ZNTL option chain right now, and a simple map from your view on ZNTL to the strategy that fits it. Model any of them in the calculator before you trade.
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals is a clinical-stage biotech company headquartered in San Diego that develops small-molecule cancer drugs. Its lead candidate, azenosertib, is being tested in a Phase 3 trial for ovarian cancer and other solid tumors. The company also operates earlier-stage studies examining azenosertib as a monotherapy in various cancers and in combination approaches for patients whose tumors have become resistant to PARP inhibitors. The firm maintains licensing arrangements and collaborative relationships with external partners, including Recurium IP Holdings, to support its research and development efforts.
Since Zentalis remains in clinical development stages rather than commercializing approved medicines, it generates minimal product revenue. The company's financial model depends on funding from investors, grants, and potentially milestone payments tied to clinical progress from its licensing partners. Its market presence is limited to the research and development sphere, without yet competing in the commercial oncology marketplace. The company's value proposition centers on the potential clinical utility of its drug candidates and the intellectual property…
Today's top-scoring strategy for ZNTL
Our engine ranks defined-risk strategies on the live ZNTL chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $4 | $0.01 |
| Sell | 1× | PUT | $5 | $0.12 |
Simulazione
Simulazione prospettica di 6,000 traiettorie di prezzo lognormali fino alla scadenza — non è un backtest storico.
Analisi della strategia
Greche vs prezzo
Prezzo × volatilità (oggi)
| −30% | −15% | IV | +15% | +30% | |
|---|---|---|---|---|---|
| $6 | $11 | $11 | $11 | $11 | $11 |
| $6 | $11 | $11 | $11 | $11 | $10 |
| $6 | $11 | $11 | $10 | $10 | $9 |
| $6 | $11 | $10 | $9 | $8 | $6 |
| $5 | $9 | $8 | $6 | $4 | $2 |
| $5 | $4 | $2 | −$1 | −$4 | −$6 |
| $5 | −$8 | −$10 | −$13 | −$15 | −$17 |
| $5 | −$27 | −$28 | −$30 | −$31 | −$32 |
| $4 | −$50 | −$50 | −$49 | −$49 | −$48 |
| $4 | −$71 | −$70 | −$68 | −$66 | −$64 |
| $4 | −$84 | −$82 | −$80 | −$78 | −$77 |
Illustrative example at ZNTL's latest available price, computed with the same engine as the tool. Live option fills and the real IV skew refresh during US market hours.
Implied volatility
ZNTL is currently trading with moderate implied volatility, broadly in line with other large-cap stocks. On the options we scanned that was around 32% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on ZNTL currently price in about 32% implied volatility, versus roughly 88% the stock has actually realised over the past month. That makes options relatively cheap — an edge for strategies that buy premium, such as long calls, long puts and debit spreads.
Off that volatility, the options market is pricing a move of about ±$0,47 (±9%) in ZNTL by 2026-08-21 — a range of roughly $4,68 to $5,62. Strikes inside that band hold most of the premium and see most of the action.
Insider trading su ZNTL (SEC Form 4)
Operazioni degli insider sul mercato aperto relative a ZNTL negli ultimi sei mesi circa, tratte dalle comunicazioni SEC Form 4. Gli acquisti sul mercato aperto sono il segnale più raro e più forte — le vendite di routine effettuate nell'ambito di piani prestabiliti sono frequenti, quindi leggi un dato di vendita netta tenendolo presente.
| Insider | Azione | Azioni | Valore | Data |
|---|---|---|---|---|
| Vultaggio Vincent | Vendita | 6894 | $17K | 2026-02-10 |
| Vultaggio Vincent | Vendita | 3379 | $8K | 2026-02-09 |
| Bruns Ingmar | Vendita | 335 | $802 | 2026-02-09 |
| EASTLAND JULIA MARIE | Vendita | 889 | $2K | 2026-02-09 |
| Vultaggio Vincent | Vendita | 29.951 | $73K | 2026-02-06 |
| Bruns Ingmar | Vendita | 2962 | $7K | 2026-02-06 |
Fonte: comunicazioni SEC Form 4 tramite Finnhub. Solo acquisti (P) e vendite (S) sul mercato aperto — assegnazioni, esercizi di opzioni, donazioni e ritenute fiscali sono esclusi. Contesto informativo, non consulenza sugli investimenti.
Earnings & IV crush
ZNTL's next earnings report is due around 6 agosto 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
With earnings roughly 15 days out, ZNTL's 32% implied volatility is inflated by event premium — and it usually collapses the moment results drop ("IV crush"). That rewards defined-risk premium sellers when the move stays muted, and punishes option buyers who paid the inflated price. Keep size small and risk defined through the report.
Key figures
- Market cap
- $320M
- Beta (vs market)
- 1.93
- 52-week range
- $1.21–$6.95 (69% up the range)
- Short interest
- 10.3% of float · 4.4 days to cover
With 10.3% of ZNTL's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
How to choose an options strategy for ZNTL
Start with your outlook on ZNTL, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while ZNTL stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →⧉ Embed this free calculator on your site →
How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open ZNTL in the free calculator →
Domande frequenti
What is the best options strategy for ZNTL?
It depends on your outlook. Bullish traders often use a long call or bull call spread on ZNTL; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are ZNTL options liquid enough to trade?
Zentalis Pharmaceuticals, Inc. (ZNTL) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade ZNTL options?
Buying a single ZNTL call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade ZNTL or any security. Do your own research.
Cosa fa Zentalis Pharmaceuticals, Inc.?
Zentalis Pharmaceuticals, Inc. (ZNTL) opera nel settore Biotechnology. La sezione "Informazioni su Zentalis Pharmaceuticals, Inc." qui sopra offre un quadro più completo di ciò che fa l'azienda e di come genera profitti.
Zentalis Pharmaceuticals, Inc. paga dividendi?
Qui non mostriamo un rendimento da dividendo confermato per Zentalis Pharmaceuticals, Inc., quindi consideralo incerto: prima di scrivere delle call controlla il dividendo attuale e la data di stacco cedola (ex-dividend) presso il tuo broker — una data di stacco imminente può innescare un'assegnazione anticipata sulle call scritte in-the-money.
Quando Zentalis Pharmaceuticals, Inc. pubblica gli utili?
I prossimi utili di Zentalis Pharmaceuticals, Inc. sono attesi intorno al 6 agosto 2026. La volatilità implicita di solito sale in avvicinamento alla pubblicazione e crolla bruscamente dopo (IV crush) — un aspetto importante per qualsiasi posizione in opzioni che mantieni oltre quella data.
Tickers related to ZNTL
Comparing ZNTL with similar names can help you choose the best options strategy:
Informazioni sull’azienda
- Sede
- 10275 Science Center Dr., Suite 200, San Diego, CA, 92121, United States
- Settore
- Biotechnology
- Dipendenti
- 106
- CEO
- Ms. Julie M. Eastland M.B.A.
- Telefono
- 858 263 4333
- Sito web
- zentalis.com
Best Options Strategy by Ticker →
Solo per uso didattico. Le quotazioni sono ritardate di circa 15 minuti e nulla di ciò che è riportato qui è consulenza finanziaria. Il trading di opzioni comporta un rischio sostanziale di perdita. Privacy · Terms.